Compositions comprising an FC domain for the treatment of medical conditions

The use of Fc domain-specific T cells with enhanced binding capabilities generates memory cells that effectively target and eradicate cancer cells, addressing the limitations of current therapies in treating refractory and metastatic cancers by promoting long-term immune recognition and response.

WO2024236557A1PCT designated stage expired Publication Date: 2024-11-21GILBOA THERAPEUTICS LTD
View PDF 26 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2023/050709
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2023-07-07
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current cancer therapies, including cancer immunotherapy and cell-based therapies, face challenges in effectively targeting cancer cells while sparing healthy tissues, particularly in cases of metastatic or relapsed cancers that have been refractory to previous treatments, due to limited recognition spectrum and difficulty in obtaining antigen-specific effector lymphocytes.

Method used

A therapeutic composition comprising an Fc domain is administered to subjects who are non-naive to Fc-mediated immune cell therapy, utilizing T cells expressing a receptor with an extracellular binding domain capable of binding the Fc domain, such as CD64, to generate memory cells that can persist and recognize cancer cells, enhancing anti-tumor activity.

Benefits of technology

The approach results in increased survival rates and tumor eradication, with persistent memory T cells able to recognize and target cancer cells, even in second challenges, indicating long-term immunity and effective treatment of metastatic or relapsed cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000052
    Figure 000052
  • Figure 000053
    Figure 000053
  • Figure 000054
    Figure 000054
Patent Text Reader

Abstract

Compositions comprising an Fc domain for the treatment of medical conditions are provided. Accordingly, there is provided a method of treating a medical condition associated with pathological cells in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a therapeutic composition comprising an Fc domain and having specificity to the pathological cells, wherein said subject is non naive to an Fc- mediated immune cell therapy and comprises memory cells of said immune cell therapy in a lymphoid organ sample.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] COMPOSITIONS COMPRISING AN FC DOMAIN FOR THE TREATMENT OF MEDICAL

[0002] CONDITIONS

[0003] RELATED APPLICATION / S

[0004] This application claims the benefit of priority of US Patent Application No. 63 / 465,892 filed on May 12, 2023, the contents of which are incorporated herein by reference in their entirety.

[0005] SEQUENCE LISTING STATEMENT

[0006] The XML file, entitled 95813 Sequence Listing. xml, created on 7 July 2023, comprising 16,384 bytes, submitted concurrently with the filing of this application is incorporated herein by reference.

[0007] FIELD AND BACKGROUND OF THE INVENTION

[0008] The present invention, in some embodiments thereof, relates to compositions comprising an Fc domain for the treatment of medical conditions.

[0009] Cancer therapy, including first-line and second-line therapies, depend on many factors, including the type and stage of cancer, the patient’s overall health, medical history and the response to previous treatments.

[0010] Cancer immunotherapy, including cell-based therapy, antibody therapy, cytokine therapy and combinations thereof, has emerged in the last years as a promising strategy for treating various types of cancer owing to its potential to evade genetic and cellular mechanisms of drug resistance and to target tumor cells while sparing healthy tissues.

[0011] Antibody-based cancer immunotherapies, such as monoclonal antibodies, antibodyfusion proteins, and antibody drug conjugates (ADCs) depend on recognition of cell surface molecules that are differentially expressed on cancer cells relative to non-cancerous cells and / or immune-checkpoint blockade. Binding of an antibody-based immunotherapy to a cancer cell can lead to cancer cell death via various mechanisms, e.g., antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), direct cytotoxic activity of the payload from an antibody-drug conjugate (ADC) or suppressive checkpoint blockade. Many of these mechanisms initiate through the binding of the Fc domain of cell-bound antibodies to specialized cell surface receptors (Fc receptors) on hematopoietic cells.

[0012] Cell-based therapy using e.g. T cells having a T cell receptor (TCR) specific for an antigen differentially expressed in association with an MHC class I molecule on cancer cells relative to non-cancerous cells were shown to exert anti-tumor effects in several types of cancers, e.g. hematologic malignancies. However, antigen- specific effector lymphocytes, are very rare, individual-specific, limited in their recognition spectrum and difficult to obtain against most malignancies.

[0013] Strategies combining principles of antibody-based cancer immunotherapy and cell based therapy, such as CAR T cells and combined treatment with antibodies and T cells expressing Fc receptors have been disclosed (see e.g. EP Patent No: EP0340793; International Patent Application Publication Nos: WO2017205254, WO2015179833, W02020 / 188570 and WO202 1 / 260696; US Patent Application Publication Nos: US20150139943, US20180008638 and US20160355566; US Patent No. US 10577417; Clemenceau et al. Blood. 2006; 107:4669- 4677; and Urbanska et al. Molecular Therapy. 2014; 22(Supplement 1): S297-S298).

[0014] SUMMARY OF THE INVENTION

[0015] According to an aspect of some embodiments of the present invention there is provided a method of treating a medical condition associated with pathological cells in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a therapeutic composition comprising an Fc domain and having specificity to the pathological cells, wherein the subject is non naive to an Fc-mediated immune cell therapy and comprises memory cells of the immune cell therapy in a lymphoid organ sample.

[0016] According to an aspect of some embodiments of the present invention there is provided a therapeutic composition comprising an Fc domain and having specificity to pathological cells for use in treating a medical condition associated with the pathological cells in a subject in need thereof, wherein the subject is non naive to an Fc-mediated immune cell therapy and comprises memory cells of the immune cell therapy in a lymphoid organ sample.

[0017] According to some embodiments of the invention, the medical condition is cancer and the pathological cell is a cancerous cell.

[0018] According to some embodiments of the invention, the cancer is a metastatic cancer.

[0019] According to some embodiments of the invention, the cancer is a recurred or relapsed cancer.

[0020] According to some embodiments of the invention, the cancer has been refractory to previous treatment with the Fc- mediated immune cell therapy.

[0021] According to some embodiments of the invention, the Fc-mediated immune cell therapy further comprised a therapeutic composition comprising an Fc domain and having specificity to a pathological cell. According to some embodiments of the invention, the therapeutic composition is an Fc- fusion protein.

[0022] According to some embodiments of the invention, the therapeutic composition is an antibody.

[0023] According to some embodiments of the invention, the Fc-mediated immune cell therapy comprises an immune cell expressing a receptor or a protein complex having an extracellular antigen binding domain of an antibody specific for the Fc domain.

[0024] According to some embodiments of the invention, the Fc- mediated immune cell therapy comprises an immune cell expressing a receptor or a protein complex having an extracellular binding domain of an Fc receptor capable of binding the Fc domain.

[0025] According to some embodiments of the invention, the Fc-mediated immune cell therapy comprises an immune cell expressing a receptor and a co-receptor, wherein the co-receptor comprises an intracellular signaling domain, and the receptor comprises an extracellular binding domain of an Fc receptor capable of binding the Fc domain and an amino acid sequence capable of recruiting the co-receptor, such that upon binding of the extracellular binding domain to the Fc domain the signaling is transmitted in the immune cell.

[0026] According to some embodiments of the invention, the receptor further comprises a cytoplasmic domain comprising the intracellular signaling domain of the co-receptor.

[0027] According to some embodiments of the invention, the co-receptor is an Fc receptor common y chain (FcRy).

[0028] According to some embodiments of the invention, the Fc receptor is Fey receptor.

[0029] According to some embodiments of the invention, the Fey receptor is CD64.

[0030] According to some embodiments of the invention, the immune cell is a T cell.

[0031] According to some embodiments of the invention, the memory cell is an effector memory cell.

[0032] According to some embodiments of the invention, the cancer is selected from the group consisting of melanoma, lymphoma, breast cancer, gastric cancer and ovarian cancer.

[0033] According to some embodiments of the invention, the cancer is selected from the group consisting of lymphoma and gastric cancer.

[0034] According to some embodiments of the invention, the method or the use being effected at least 2 months following the Fc-mediated immune cell therapy.

[0035] According to some embodiments of the invention, the method or the use being effected following determining presence of the Fc-mediated immune cells in a lymphoid organ sample of the subject. According to some embodiments of the invention, the method or the use being at least a second line treatment.

[0036] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and / or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

[0037] BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

[0038] Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

[0039] In the drawings:

[0040] FIGs. 1A-D demonstrate the therapeutic effect of AG2G-expressing T cells + rituximab in a mouse lymphoma tumor model. NSG mice were inoculated with Raji-Luc (IxlO6cells / mouse, i.v., n=8,). AG2G-expressing T cells (IxlO7cells / mouse, i.v.) were administered 1 day following tumor inoculation. Rituximab’s first dose (250 pg / mouse) was administered on day 1 and consecutive dosing (125 pg / mouse) were performed weekly. Figure 1A shows images and Figure IB is a representing graph demonstrating tumor growth, as evaluated by IVIS scan up to 21 days post tumor inoculation. Figures 1C-D show graphs demonstrating mice survival (Figure 1C) and weight (Figure ID), with time point starting from tumor cells inoculation until termination of the experiment on day 41 post tumor inoculation. In Figure ID: # - 8 mice died (on day 21), % - 1 mouse died; & - 2 mice died.

[0041] FIGs. 2A-D show T cells phenotypes, as determined by flow cytometry. Figure 2A shows the phenotypes of AG2G-transduced T cells after transduction. Following, the AG2G-expressing T cells were administered to a mouse lymphoma tumor model in combination with rituximab (n=8). Mice were sacrificed on day 41, the bone marrow was extracted and the cells were stained for the human markers CD45, CD3, CD45RO and CCR7 and evaluated by flow cytometry. Figure 2B shows the phenotypes of cells gated on human CD45+CD3+ of 5 mice which were completely cleared from tumor cells (i.e. complete responders). Figure 2C shows the phenotypes of cells gated on human CD45+CD3+ of 3 mice which were not completely cleared from tumor cells (i.e. non-complete responders). Figure 2D is a graph representation of the CD45ROhlghCCR7loweffector memory T cells populations shown in Figures 2B-C.

[0042] FIGs. 3A-B demonstrate the therapeutic effect of AG2G-expressing T cells + trastuzumab in a mouse HER2 positive gastric carcinoma model. NSG mice were inoculated with 3xl06NCI-N87 cells. After 13 days, mice were treated with non-transduced T cells or AG2G-trasnduced T cells (i.v.) in combination with trastuzumab (200 pg / mouse, i.p.) (n=5 in each group). Tumor growth was monitored for 33 more days. On day 85, 4 of the 5 mice treated with the AG2G-trasnduced T cells + trastuzumab that completely recovered were re-challenged with 3xl06NCI-N87 cells (the fifth mouse from this group had a small tumor and thus was sacrificed and excluded from re-challenge part of the experiment). In addition, as a control, a new group of naive mice (n=4) were inoculated at the same day with 3xl06NCI-N87 cells as well. After 13 more days (day 98 from initial inoculation) mice were treated with trastuzumab (200 pg / mouse, i.p.) and tumor growth was monitored. Shown is tumor volume over time, separated to first tumor administration (left) and second tumor administration (right). Next, mice were sacrificed on day 131, the bone marrow was extracted, the cells were stained for human CD3 / CCR7 / CD45RO and evaluated by flow cytometry. Figure 3B shows the phenotype of cells gated on human CD3+ of the re-challenged mice (which were treated with the AG2G-trasnduced T cells + trastuzumab following the 1stchallenge and with trastuzumab alone following the 2ndchallenge).

[0043] FIGs. 4A-B demonstrate the therapeutic effect of AG2G-expressing T cells + trastuzumab in a mouse HER2 positive gastric carcinoma model. NSG mice were inoculated with 3X106NCI-N87 cells. When tumors reached ~70 mm3, mice were injected with single dose of AG2G-transduced T cells (i.v.) in combination with weekly administrations of trastuzumab (125 pg / mouse i.p.). As controls, mice were injected with saline alone or in combination with trastuzumab. Tumor growth was monitored for additional 56 days. Figure 4A shows tumor volume over time in the three treatment groups. Figure 4B shows the phenotypes of AG2G- transduced T cells prior to injection and of human CD3+ gated bone marrow cells extracted from the treated mice on day 56.

[0044] DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION The present invention, in some embodiments thereof, relates to compositions comprising an Fc domain for the treatment of medical conditions.

[0045] Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

[0046] Cancer immunotherapy, including cell-based therapy, antibody therapy and cytokine therapy, has emerged in the last couple of years as a promising strategy for treating various types of cancer. Antibody-based cancer immunotherapies depend on recognition of cell surface molecules that are differentially expressed on cancer cells relative to non-cancerous cells and / or immune-checkpoint blockade. On the other hand, cell-based therapy using e.g. T cells having a T cell receptor (TCR) specific for an antigen differentially expressed in association with an MHC class I molecule on cancer cells relative to non-cancerous cells were shown to exert anti-tumor effects in several types of cancers, e.g. hematologic malignancies. Strategies combining principles of antibody-based cancer immunotherapy and cell based therapy have been suggested.

[0047] Specific embodiments of the present invention suggest that combined treatment of a pathological condition with an antibody and immune cells expressing a receptor capable of binding the Fc domain of the antibody results in presence of the immune cells in the treated subject for long periods of times, enabling generation of a memory which can be harnessed to the success of following treatments.

[0048] While reducing specific embodiments of the present invention to practice, the present inventors exemplified the above concept using T cells recombinantly expressing a receptor comprising the amino acid sequence of the high affinity Fey receptor FcyRI (CD64) fused to the intracellular domain of the Fc receptor common y chain (FcRy), and an FcRy co-receptor, referred to herein as FcgRI-alpha-gamma-2A-Gamma (AG2G). These T cells were previously described in International Patent Application Publication No. WO2021 / 260696 and were shown to have anti-tumor activities both in-vitro and in-vivo, only when administrated in combination with a tumor-binding antibody. As shown in the Examples section which follows, the present inventors have shown in two different mice tumor models that these cells are conserved in the treated mice for long periods of time as memory cells which can be detected in the bone marrow of the treated mice (Examples 1-3 of the Examples section which follows). Specifically, using a lymphoma tumor model, combined treatment with the human AG2G-expressing T cells and rituximab lead to increased survival compared to mice treated with rituximab alone, wherein increased percentage of human effector memory T cells in the bone marrow was correlated with the anti-tumor activity (Example 1 of the Examples section which follows). In a solid HER2 positive tumor model, combined treatment with the human AG2G-expressing T cells and trastuzumab lead to tumor eradication and was associated with presence of human effector memory T cells in the bone marrow (Examples 2-3 of the Examples section which follows). Furthermore, re-challenging these mice with a second tumor about three months following treatment with the AG2G-expressing T cells, followed by treatment with trastuzumab alone lead to elimination of the second tumor; indicating persistence of AG2G-expressing memory T cells in the treated mice (as also verified by flow cytometry analysis of bone marrow of treated mice) (Example 3 of the Examples section which follows).

[0049] Thus, according to an aspect of the present invention, there is provided a method of treating a medical condition associated with pathological cells in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a therapeutic composition comprising an Fc domain and having specificity to the pathological cells, wherein said subject is non naive to an Fc-mediated immune cell therapy and comprises memory cells of said immune cell therapy in a lymphoid organ sample.

[0050] According to an additional or an alternative aspect of the present invention, there is provided a therapeutic composition comprising an Fc domain and having specificity to pathological cells for use in treating a medical condition associated with said pathological cells in a subject in need thereof, wherein said subject is non naive to an Fc-mediated immune cell therapy and comprises memory cells of said immune cell therapy in a lymphoid organ sample.

[0051] As used herein the term “treating” refers to curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of a medical condition associated with pathological cells (e.g. cancer). Those of skill in the art will understand that various methodologies and assays can be used to assess the development of a pathology, and similarly, various methodologies and assays may be used to assess the reduction, remission or regression of a pathology (e.g. a malignancy), as discussed below.

[0052] As used herein the phrase “a medical disorder associated with pathological cells” refers to a medical disorder characterized by pathological cells which drive the onset and / or progression of the medical condition

[0053] According to specific embodiments, the medical condition is a recurred or relapsed medical condition.

[0054] According to specific embodiments, the medical condition has been refractory to a previous treatment comprising an Fc-mediated immune cell therapy. According to specific embodiments, the medical disorder can benefit from activating the immune cells of the subject.

[0055] As used herein the phrase “a medical condition that can benefit from activating immune cells” refers to diseases in which the subject’s immune response activity may be sufficient to at least ameliorate symptoms of the disease or delay onset of symptoms, however for any reason the activity of the subject’s immune response in doing so is less than optimal.

[0056] Non-limiting examples of medical disorders treated by some embodiments of the invention include hyper-proliferative diseases, diseases associated with immune suppression, immunosuppression caused by medication (e.g. mTOR inhibitors, calcineurin inhibitor, steroids) and infections.

[0057] According to specific embodiments, the medical condition comprises an infection.

[0058] As used herein, the term “infection” or "infectious disease" refers to a disease induced by a pathogen. Specific examples of pathogens include, viral pathogens, bacterial pathogens e.g., intracellular mycobacterial pathogens (such as, for example, Mycobacterium tuberculosis), intracellular bacterial pathogens (such as, for example, Listeria monocytogenes), or intracellular protozoan pathogens (such as, for example, Leishmania and Trypanosoma).

[0059] Specific types of viral pathogens causing infectious diseases include, but are not limited to, retroviruses, circoviruses, parvoviruses, papovaviruses, adenoviruses, herpesviruses, iridoviruses, poxviruses, hepadnaviruses, picornaviruses, caliciviruses, togaviruses, flaviviruses, reoviruses, orthomyxoviruses, paramyxoviruses, rhabdoviruses, bunyaviruses, coronaviruses, arenaviruses, and filoviruses.

[0060] Specific examples of viral infections which may be treated according to specific embodiments of the present invention include, but are not limited to, human immunodeficiency virus (HlV)-induced acquired immunodeficiency syndrome (AIDS), influenza, rhinoviral infection, viral meningitis, Epstein-Barr virus (EBV) infection, hepatitis A, B or C virus infection, measles, papilloma virus infection / warts, cytomegalovirus (CMV) infection, Herpes simplex virus infection, yellow fever, Ebola virus infection, rabies, etc.

[0061] According to specific embodiments, the medical condition comprises a hyper- proliferative disease.

[0062] According to specific embodiments, the hyper-proliferative disease comprises sclerosis, fibrosis, Idiopathic pulmonary fibrosis, psoriasis, systemic sclerosis / scleroderma, primary biliary cholangitis, primary sclerosing cholangitis, liver fibrosis, prevention of radiation-induced pulmonary fibrosis, myelofibrosis or retroperitoneal fibrosis. According to other specific embodiments, the hyper-proliferative disease comprises cancer.

[0063] Thus, according to specific embodiments the pathological cell is a cancerous cell.

[0064] Cancers which may be treated by some embodiments of the invention can be any solid or non- solid tumor (including liquid cancer), cancer metastasis and / or a pre-cancer.

[0065] According to specific embodiments, the cancer is a malignant cancer.

[0066] Examples of cancer include but are not limited to, carcinoma, blastoma, sarcoma and lymphoma. More particular examples of such cancers include, but are not limited to, tumors of the gastrointestinal tract (colon carcinoma, rectal carcinoma, colorectal carcinoma, colorectal cancer, colorectal adenoma, hereditary nonpolyposis type 1, hereditary nonpolyposis type 2, hereditary nonpolyposis type 3, hereditary nonpolyposis type 6; colorectal cancer, hereditary nonpolyposis type 7, small and / or large bowel carcinoma, esophageal carcinoma, tylosis with esophageal cancer, stomach carcinoma, pancreatic carcinoma, pancreatic endocrine tumors), endometrial carcinoma, dermatofibrosarcoma protuberans, gallbladder carcinoma, Biliary tract tumors, prostate cancer, prostate adenocarcinoma, renal cancer (e.g., Wilms’ tumor type 2 or type 1), liver cancer (e.g., hepatoblastoma, hepatocellular carcinoma, hepatocellular cancer), bladder cancer, embryonal rhabdomyosarcoma, germ cell tumor, trophoblastic tumor, testicular germ cells tumor, immature teratoma of ovary, uterine, epithelial ovarian, sacrococcygeal tumor, choriocarcinoma, placental site trophoblastic tumor, epithelial adult tumor, ovarian carcinoma, serous ovarian cancer, ovarian sex cord tumors, cervical carcinoma, uterine cervix carcinoma, small-cell and non-small cell lung carcinoma, nasopharyngeal, breast carcinoma (e.g., ductal breast cancer, invasive intraductal breast cancer, sporadic ; breast cancer, susceptibility to breast cancer, type 4 breast cancer, breast cancer- 1, breast cancer-3; breast-ovarian cancer), squamous cell carcinoma (e.g., in head and neck), neurogenic tumor, astrocytoma, ganglioblastoma, neuroblastoma, lymphomas (e.g., Hodgkin's disease, non-Hodgkin's lymphoma, B cell, Burkitt, cutaneous T cell, histiocytic, lymphoblastic, T cell, thymic), gliomas, adenocarcinoma, adrenal tumor, hereditary adrenocortical carcinoma, brain malignancy (tumor), various other carcinomas (e.g., bronchogenic large cell, ductal, Ehrlich-Lettre ascites, epidermoid, large cell, Lewis lung, medullary, mucoepidermoid, oat cell, small cell, spindle cell, spinocellular, transitional cell, undifferentiated, carcinosarcoma, choriocarcinoma, cystadenocarcinoma), ependimoblastoma, epithelioma, erythroleukemia (e.g., Friend, lymphoblast), fibrosarcoma, giant cell tumor, glial tumor, glioblastoma (e.g., multiforme, astrocytoma), glioma hepatoma, heterohybridoma, heteromyeloma, histiocytoma, hybridoma (e.g., B cell), hypernephroma, insulinoma, islet tumor, keratoma, leiomyoblastoma, leiomyosarcoma, leukemia (e.g., acute lymphatic, acute lymphoblastic, acute lymphoblastic pre-B cell, acute lymphoblastic T cell leukemia, acute - megakaryoblastic, monocytic, acute myelogenous, acute myeloid, acute myeloid with eosinophilia, B cell, basophilic, chronic myeloid, chronic, B cell, eosinophilic, Friend, granulocytic or myelocytic, hairy cell, lymphocytic, megakaryoblastic, monocytic, monocytic- macrophage, myeloblastic, myeloid, myelomonocytic, plasma cell, pre-B cell, promyelocytic, subacute, T cell, lymphoid neoplasm, predisposition to myeloid malignancy, acute nonlymphocytic leukemia), lymphosarcoma, melanoma, mammary tumor, mastocytoma, medulloblastoma, mesothelioma, metastatic tumor, monocyte tumor, multiple myeloma, myelodysplastic syndrome, myeloma, nephroblastoma, nervous tissue glial tumor, nervous tissue neuronal tumor, neurinoma, neuroblastoma, oligodendroglioma, osteochondroma, osteomyeloma, osteosarcoma (e.g., Ewing's), papilloma, transitional cell, pheochromocytoma, pituitary tumor (invasive), plasmacytoma, retinoblastoma, rhabdomyosarcoma, sarcoma (e.g., Ewing's, histiocytic cell, Jensen, osteogenic, reticulum cell), schwannoma, subcutaneous tumor, teratocarcinoma (e.g., pluripotent), teratoma, testicular tumor, thymoma and trichoepithelioma, gastric cancer, fibrosarcoma, glioblastoma multiforme; multiple glomus tumors, Li-Fraumeni syndrome, liposarcoma, lynch cancer family syndrome II, male germ cell tumor, mast cell leukemia, medullary thyroid, multiple meningioma, endocrine neoplasia myxosarcoma, paraganglioma, familial nonchromaffin, pilomatricoma, papillary, familial and sporadic, rhabdoid predisposition syndrome, familial, rhabdoid tumors, soft tissue sarcoma, and Turcot syndrome with glioblastoma.

[0067] According to specific embodiments, the cancer is a pre-malignant cancer.

[0068] Pre-cancers are well characterized and known in the art (refer, for example, to Berman JJ. and Henson DE., 2003. Classifying the pre-cancers: a metadata approach. BMC Med Inform Decis Mak. 3:8). Examples of pre-cancers include, but are not limited to, acquired small pre- cancers, acquired large lesions with nuclear atypia, precursor lesions occurring with inherited hyperplastic syndromes that progress to cancer, and acquired diffuse hyperplasias and diffuse metaplasias. Non-limiting examples of small pre-cancers include HGSIL (High grade squamous intraepithelial lesion of uterine cervix), AIN (anal intraepithelial neoplasia), dysplasia of vocal cord, aberrant crypts (of colon), PIN (prostatic intraepithelial neoplasia).

[0069] Non-limiting examples of acquired large lesions with nuclear atypia include tubular adenoma, AILD (angioimmunoblastic lymphadenopathy with dysproteinemia), atypical meningioma, gastric polyp, large plaque parapsoriasis, myelodysplasia, papillary transitional cell carcinoma in-situ, refractory anemia with excess blasts, and Schneiderian papilloma. Nonlimiting examples of precursor lesions occurring with inherited hyperplastic syndromes that progress to cancer include atypical mole syndrome, C cell adenomatosis and MEA. Non-limiting examples of acquired diffuse hyperplasias and diffuse metaplasias include Paget's disease of bone and ulcerative colitis.

[0070] Examples of solid tumors that can be treated by the instant methods include tumors and / or metastasis (wherever located) other than lymphatic cancer, for example brain and other central nervous system tumors (including but not limited to tumors of the meninges, brain, spinal cord, cranial nerves and other parts of central nervous system, e.g. glioblastomas or medulla blastomas); head and / or neck cancer; breast tumors; circulatory system tumors (including but not limited to heart, mediastinum and pleura, and other intrathoracic organs, vascular tumors and tumor-associated vascular tissue); excretory system tumors (including but not limited to tumors of kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs); gastrointestinal tract tumors (including but not limited to tumors of esophagus, stomach, small intestine, colon, colorectal, rectosigmoid junction, rectum, anus and anal canal, tumors involving the liver and intrahepatic bile ducts, gall bladder, other and unspecified parts of biliary tract, pancreas, other and digestive organs); oral cavity tumors (including but not limited to tumors of lip, tongue, gum, floor of mouth, palate, and other parts of mouth, parotid gland, and other parts of the salivary glands, tonsil, oropharynx, nasopharynx, pyriform sinus, hypopharynx, and other sites in the lip, oral cavity and pharynx); reproductive system tumors (including but not limited to tumors of vulva, vagina, Cervix uteri, Corpus uteri, uterus, ovary, and other sites associated with female genital organs, placenta, penis, prostate, testis, and other sites associated with male genital organs); respiratory tract tumors (including but not limited to tumors of nasal cavity and middle ear, accessory sinuses, larynx, trachea, bronchus and lung, e.g. small cell lung cancer or nonsmall cell lung cancer); skeletal system tumors (including but not limited to tumors of bone and articular cartilage of limbs, bone articular cartilage and other sites); skin tumors (including but not limited to malignant melanoma of the skin, non-melanoma skin cancer, basal cell carcinoma of skin, squamous cell carcinoma of skin, mesothelioma, Kaposi's sarcoma); and tumors involving other tissues including peripheral nerves and autonomic nervous system, connective and soft tissue, retroperitoneum and peritoneum, eye and adnexa, thyroid, adrenal gland and other endocrine glands and related structures, secondary and unspecified malignant neoplasm of lymph nodes, secondary malignant neoplasm of respiratory and digestive systems and secondary malignant neoplasm of other sites.

[0071] In some examples, the solid tumor treated by the methods of the instant disclosure is pancreatic cancer, bladder cancer, colon cancer, liver cancer, colorectal cancer (colon cancer or rectal cancer), breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors, bone cancer, skin cancer, ocular tumor, choriocarcinoma (tumor of the placenta), sarcoma or soft tissue cancer.

[0072] In some examples, the solid tumor to be treated by the methods of the instant disclosure is selected bladder cancer, bone cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, ocular tumor, renal cancer, liver cancer, lung cancer, pancreatic cancer, choriocarcinoma (tumor of the placenta), prostate cancer, sarcoma, skin cancer, soft tissue cancer or gastric cancer.

[0073] In some examples, the solid tumor treated by the methods of the instant disclosure is breast cancer. Non-limiting examples of breast cancer that can be treated by the instant methods include ductal carcinoma in situ (DCIS or intraductal carcinoma), lobular carcinoma in situ (LCIS), invasive (or infiltrating) ductal carcinoma, invasive (or infiltrating) lobular carcinoma, inflammatory breast cancer, triple-negative breast cancer, paget disease of the nipple, phyllodes tumor (phylloides tumor or cystosarcoma phyllodes), angiosarcoma, adenoid cystic (or adenocystic) carcinoma, low-grade adenosquamous carcinoma, medullary carcinoma, papillary carcinoma, tubular carcinoma, metaplastic carcinoma, micropapillary carcinoma, and mixed carcinoma.

[0074] In some examples, the solid tumor treated by the methods of the instant disclosure is bone cancer. Non-limiting examples of bone cancer that can be treated by the instant methods include osteosarcoma, chondrosarcoma, the Ewing Sarcoma Family of Tumors (ESFTs).

[0075] In some examples, the solid tumor treated by the methods of the instant disclosure is skin cancer. Non-limiting examples of skin cancer that can be treated by the instant methods include melanoma, basal cell skin cancer, and squamous cell skin cancer.

[0076] In some examples, the solid tumor treated by the methods of the instant disclosure is ocular tumor. Non-limiting examples of ocular tumor that can be treated by the methods of the instant disclosure include ocular tumor is choroidal nevus, choroidal melanoma, choroidal metastasis, choroidal hemangioma, choroidal osteoma, iris melanoma, uveal melanoma, intraocular lymphoma, melanocytoma, metastasis retinal capillary hemangiomas, congenital hypertrophy of the RPE, RPE adenoma or retinoblastoma.

[0077] In some embodiments, cancers that are treated are liquid cancers. Examples of liquid cancers that can be treated by the methods provided herein include, but are not limited to, leukemias, myelomas, and liquid lymphomas. In specific embodiments, liquid cancers that can be treated in accordance with the methods described include, but are not limited to, liquid lymphomas, leukemias, and myelomas. Exemplary liquid lymphomas and leukemias that can be treated in accordance with the methods described include, but are not limited to, acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma (such as waldenstrom macroglobulinemia), splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, monoclonal immunoglobulin deposition diseases, heavy chain diseases, extranodal marginal zone B cell lymphoma, also called malt lymphoma, nodal marginal zone B cell lymphoma (nmzl), follicular lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt lymphoma / leukemia, T cell prolymphocytic leukemia, T cell large granular lymphocytic leukemia, aggressive NK cell leukemia, adult T cell leukemia / lymphoma, extranodal NK / T cell lymphoma, nasal type, enteropathy-type T cell lymphoma, hepatosplenic T cell lymphoma, blastic NK cell lymphoma, mycosis fungoides / sezary syndrome, primary cutaneous CD30-positive T cell lymphoproliferative disorders, primary cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, angioimmunoblastic T cell lymphoma, peripheral T cell lymphoma, unspecified, anaplastic large cell lymphoma, classical Hodgkin lymphomas (nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte depleted or not depleted), and nodular lymphocyte -predominant Hodgkin lymphoma. In one aspect, myelodysplastic syndromes (MDS) is a heterogenous group of clonal, hematopoietic stem cell disorders characterized by distinct morphological bone marrow changes, abnormal blood counts, common cytogenetic abnormalities, and recurrent mutations. MDS can predominantly occur in the elderly. Treatment of MDS can be based on risk stratification, with the International Prognostic Scoring System (IPSS) or revised IPSS (IPSS-R) being the most common classification systems. Low-risk MDS patients can receive supportive care or hematopoietic growth factors. A subset of patients with 5q deletions can be treated with lenalidomide. High-risk patients can be treated with hypomethylating agents (e.g., azacitidine, decitabine), intensive chemotherapy, and / or allogeneic stem cell transplantation. In some cases, MDS patients can be transformed to AML. Some MDS patients can develop progressive bone marrow failure and / or die of complications related to neutropenia (e.g., infection) or thrombocytopenia (e.g., bleeding). Initial management of MDS can be based on risk stratification. The newer IPSS-R can place patients into 5 categories: very good, good, intermediate, high, and very-high risk groups. Patients in the very good, good, and select intermediate-risk patients can be categorized as “low- risk,” whereas high, very high, and certain intermediate-risk patients can be categorized as the “high-risk” group. Azacitidine (5 ’-azacytidine) and decitabine (5’-aza-2’-deoxycytidine), which both are cytosine analogues, can lead to inhibition of DNA-methyltransferases (DNMTs) and can act as hypomethylating agents. In another aspect, acute myeloid leukemia (AML) is characterized by the proliferation and accumulation of myeloid cells with accompanying hematopoietic failure. AML can be caused by chemical exposure, prior chemotherapy and radiation, or other environmental toxins.

[0078] According to specific embodiments, the cancer is selected from the group consisting of melanoma, lymphoma, breast cancer (e.g. carcinoma), gastric cancer (e.g. carcinoma) and ovarian cancer (e.g. carcinoma).

[0079] According to specific embodiments, the cancer is selected from the group consisting of lymphoma and gastric cancer.

[0080] According to specific embodiments, the cancerous cells express a marker selected from the group consisting of CD20, HER2, PDL-1, E-Cadherin, CD19, MUC1, TRP-1 and TRP-2.

[0081] According to specific embodiments, the cancer is a metastatic cancer.

[0082] According to specific embodiments, the cancer is a recurred or relapsed cancer.

[0083] According to specific embodiments, the cancer has been refractory to a previous treatment comprising an Fc-mediated immune cell therapy.

[0084] As used herein, the term “subject” or “subject in need thereof’ refers to mammals, preferably human beings at any age or gender that has been previously treated with an Fc- mediated immune cell therapy and thus is non-naive to treatment with such cells and comprises memory cells of the immune cells therapy in the lymphoid organs. Veterinary uses are also contemplated.

[0085] None limiting examples of lymphoid organs encompassed by specific embodiments of the invention include the bone marrow, spleen and lymph nodes.

[0086] According to specific embodiments, the lymphoid organ is the bone marrow. Methods of determining presence of immune memory cells are well known in the art and include, but not limited, flow cytometry and immunostaining of a lymphoid organ (e.g. bone marrow) samples obtained from the subject. According to specific embodiments, the memory cells are effector memory cells. None limiting markers of memory cells of the immune cell therapy that can be used with specific embodiments of the invention include, CD3+, CD4+, CD8+, CD45ROhlgh, CD45RAlow, CCR7low, CD62Llow, CD27low-1Ilt. According to specific embodiments, the low, intermediate (int) and / or high levels of expression referred to herein are determined in comparison to the cells of the immune cell therapy administered to the subject.

[0087] According to specific embodiments, the memory cells of the immune cell therapy express at least 3, at least 4, at least 5 or at least 6 of the markers disclosed above.

[0088] According to a specific embodiments, the memory cells of the immune cell therapy have a CD3+CD45ROhighCCR7lowphenotype. According to a specific embodiments, the memory cells of the immune cell therapy have a CD45ROhighCD45RAlowCCR7lowCD62LlowCD27low intphenotype.

[0089] According to specific embodiments, at least 40 %, at least 50 %, at least 60 %, at least 70 %, at least 80 %, at least 90 % of the immune cell therapy cells detected in the subject have a memory cell phenotype.

[0090] Thus, according to specific embodiments, the methods or uses disclosed herein are effected following determining presence of the Fc-mediated immune cells in a lymphoid organ (e.g. bone marrow) sample of the subject. According to specific embodiments, the subject is characterized by lymphoid organ (e.g. bone marrow) chimerism (i.e. host and donor origin immune cells). However, treatment can also be done following the realization of a sufficient exposure to the Fc-mediated immune cell therapy which allows memory cells in the lymphoid organ (e.g. bone marrow) to form. Thus, according to specific embodiments, the methods and uses of some embodiments of the invention are effected at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year following the Fc-mediated immune cell therapy.

[0091] According to a specific embodiment, the methods and uses of some embodiments of the invention are effected at least 2 months following the Fc-mediated immune cell therapy.

[0092] As the subject has been previously treated with a line of treatment comprising an Fc- mediated immune cell therapy, the methods and uses of some embodiments of the invention comprise at least a second line treatment, e.g. 3rdor 4th.

[0093] According to specific embodiments, the previous treatment with the Fc-mediated immune cell therapy resulted in complete or partial remission of the pathology.

[0094] According to specific embodiments, the subject is non-naive to Fc-mediated immune cell therapy even for the treatment of a disease other than the medical condition being treated by the instant teachings. In other words, according to specific embodiments, the medical condition being treated by the instant teachings is distinct from the medical condition treated by the Fc- mediated immune cell therapy (e.g. a different type of cancer, cancer metastasis, expressing different cell antigens etc.)

[0095] As used herein, the term “Fc-mediated immune cell therapy” refers to transplantation of immune cells (also referred to as “adoptive transfer of immune cells|”) comprising (or expressing) a receptor or a protein complex having an extracellular domain capable of binding an Fc domain (i.e. an Fc binding domain) and an intracellular signaling domain capable of transmitting an activating signal in an immune cell expressing the receptor or protein complex following binding of the Fc binding domain. According to specific embodiments, the receptor or a protein complex is a heterologous (recombinant) receptor or a protein complex.

[0096] Methods of determining expression of the receptor or protein complex are well known in the art and include, but not limited to flow cytometry or western blot.

[0097] According to specific embodiments, the immune cell therapy comprises at least O.OlxlO6cells / kg, at least O.lxlO6cells / kg, at least IxlO6cells / kg, at least 10xl06cells / kg or at least lOOxlO6cells / kg.

[0098] According to specific embodiments, the immune cell therapy comprises about O.lxlO6- 20xl06cells / kg.

[0099] As used herein, the phrase “protein complex” refers to a plurality of polypeptides not translationally fused, which together have the activity of binding a target (e.g. Fc domain) and transmitting an activating signal following said binding in an immune cell expressing the protein complex.

[0100] According to specific embodiments, the protein complex comprises 2, 3, 4, 5, 6 or more polypeptides.

[0101] According to a specific embodiment, the protein complex comprises at least 3 polypeptides.

[0102] According to a specific embodiment, the protein complex comprises 3 polypeptides.

[0103] According to specific embodiments, the plurality of polypeptides are assembled together (e.g. following binding of the extracellular binding domain to its target).

[0104] According to specific embodiments, the receptor or receptor complex is a recombinant receptor or receptor complex.

[0105] Such receptors and protein complexes and immune cells expressing same are well known in the art and described for example in International Patent Application Publication No: W02020 / 188570, WO2021 / 260696, WO17161333, WO17177217, WO17205254, WO18017649, WO18027135, W018140960 and WO18151817; US Patent Application Publication No: US2015139943 and US20080003225; US Patent No. US8313943; Beatrice Clemenceau et al. Blood. 2006; 107: 4669-4677; the contents of which are fully incorporated herein by reference.

[0106] Non-limiting examples of immune cells that can be used with specific embodiments of the invention include ACTR087 (T cells expressing CD16-41BB-CD3z by UNUM), ACTR707 (T cells expressing CD16-CD28-CD3z, by UNUM) and haNK (NK92 cells expressing CD16 158V, by Nankwest / ImmunityBio). According to specific embodiments, the immune cell is transduced with the receptor complex disclosed in International Patent Application Publication No: W02020 / 188570 and WO202 1 / 260696, the contents of which are fully incorporated herein by reference in their entirety.

[0107] As mentioned, the receptor or protein complex disclosed herein comprises an extracellular binding domain capable of binding an Fc domain (Fc binding domain).

[0108] As used herein, the phrase “extracellular binding domain” refers to a proteinaceous moiety having a binding affinity (e.g., below 10’4nM) to a target of interest. Non-limiting examples of Fc binding domains include the binding domain of an Fc receptor and an antigen binding moiety such as of an antibody, as further described hereinbelow.

[0109] Assays for testing binding are well known in the art and include, but not limited to flow cytometry, bio-layer interferometry Blitz® assay, HPLC, surface plasmon resonance (e.g. Biacore).

[0110] According to specific embodiments, the extracellular binding domain binds the target with a Kd <10’4M, <1 O’5, M <10’6M, <10’7M, <10’8M or <10’9M, each possibility represents a separate embodiment of the present invention.

[0111] According to specific embodiments, the Fc-mediated immune cell therapy comprises an immune cell comprising (or expressing) a receptor or a protein complex having an extracellular antigen binding domain of an antibody specific for the Fc domain

[0112] As used herein the phrase “extracellular antigen binding domain of an antibody” refers to at least a fragment of an antibody which comprises an antigen binding domain capable of binding an Fc domain. Detailed description on antibodies is further provided hereinbelow.

[0113] According to specific embodiments, the Fc binding domain comprises a scFv.

[0114] Thus, according to specific embodiments, the immune cell therapy comprises an immune cell transduced with a chimeric antigen receptor (CAR).

[0115] As used herein, the phrase "transduced with a CAR", “expressing a recombinant CAR”, or “genetically engineered to express a CAR” refers to cloning of a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen recognition moiety and a T-cell activation moiety. A chimeric antigen receptor (CAR) is an artificially constructed hybrid protein or polypeptide containing an antigen binding domain of an antibody (e.g., a single chain variable fragment (scFv)) linked to T-cell signaling or T-cell activation domains. Method of transducing with a CAR are known in the art and are disclosed e.g. in Davila et al. (2012) Oncoimmunology. Dec 1 ; 1(9): 1577- 1583; Wang and Riviere (2015) Cancer Gene Ther. 22(2): 85-94; Maus et al. (2014) Blood. Apr 24;123(17): 2625-35; Porter DL (2011) The New England journal of medicine, 365(8): 725-733; Jackson HJ (2016) Nat Rev Clin Oncol. 13(6): 370-383; Globerson-Levin et al. (2014) Mol Ther. 22(5): 1029-1038; June, C. H., et al. (2018) Science 359(6382): 1361-1365; Gross, G. and Z. Eshhar (2016) Annu Rev Pharmacol Toxicol 56: 59-83, the contents of which are fully incorporated herein by reference.

[0116] Non-limiting examples of CARs having an antigen binding domain specific for an Fc domain, which can be used with specific embodiments of the invention is described in US Patent Application Publication No: US20160355566 and US20210054337, the contents of which are fully incorporated herein by reference.

[0117] According to other specific embodiments, the extracellular binding domain is not an antigen binding domain of an antibody (e.g. scFv).

[0118] According to specific embodiments, the receptor and / or complex comprising same is devoid of an antigen binding domain of an antibody (e.g. scFv).

[0119] According to specific embodiments, the Fc-mediated immune cell therapy comprises an immune cell comprising (or expressing) a receptor or a protein complex having an extracellular binding domain of an Fc receptor capable of binding the Fc domain.

[0120] As used herein the phrase “extracellular binding domain of Fc receptor” refers to at least a fragment of an Fc receptor which comprises an extracellular domain capable of binding an Fc domain.

[0121] The binding domains of any known Fc receptor can be used with specific embodiments of the invention, including Fey receptors (e.g. CD64, CD32, CD16A, CD16B), Fes receptors (e.g. FcsRI, FcsRII), Fea receptors (e.g. FcaRI, CD351 and FcpR) and homologues thereof which exhibit the desired activity (i.e. binding an Fc domain). However, care should be taken to select a therapeutic composition comprising an Fc domain suitable for binding the respective Fc-binding domain.

[0122] According to specific embodiments, the Fc receptor is an Fey receptor.

[0123] As used herein, the term “Fey receptor” refers to a cell surface receptor which exhibits binding specificity to the Fc domain of an IgG antibody. Examples of Fey receptors include, without limitation, CD64A, CD64B, CD64C, CD32A, CD32B, CD16A, and CD16B. The term “Fey receptor” also encompasses functional fragments and homologues (naturally occurring or synthetically / recombinantly produced and / or comprising conservative and non-conservative amino acid substitutions), which exhibit the desired activity (e.g. capability of binding an IgG Fc domain).

[0124] According to specific embodiments, the Fey receptor is CD64. As used herein, the term “CD64”, also known as FcyRI, refers to the polypeptide expression product of the FCGR1A, FCGR1B or FCGR1C gene (corresponding to human Gene ID 2209, 2210, 2211, respectively), and includes CD64A, CD64B and CD64C. Full length CD64 comprises an extracellular, transmembrane and an intracellular domain and is capable of at least binding an IgG (IgGl and IgG3) Fc domain and recruiting an FcRy. Methods of determining binding and recruitment of an FcRy are well known in the art and are also described hereinabove and below.

[0125] According to specific embodiments, CD64 is human CD64. According to a specific embodiment, the CD64 protein refers to the human CD64A protein, such as provided in the following UniProt Number P12314 (SEQ ID NO: 1).

[0126] According to a specific embodiment, the CD64 protein refers to the human CD64B protein, such as provided in the following UniProt Number Q92637 (SEQ ID NO: 1).

[0127] According to a specific embodiment, the CD64 protein refers to the human CD64C protein, such as provided in the following GenBank Number XM_001133198 (SEQ ID NO: 3).

[0128] The extracellular domain of full length CD64 comprises three immunoglobulin (Ig) domains referred to as D1-D3 from N to C.

[0129] According to specific embodiments, the extracellular binding domain of CD64 comprises all Ig domains D1-D3.

[0130] According to specific embodiments, the extracellular binding domain of CD64 comprises SEQ ID NO: 4 or 5.

[0131] According to specific embodiments, the extracellular binding domain of CD64 consists of SEQ ID NO: 4 or 5.

[0132] According to specific embodiments, the extracellular binding domain of CD64 comprises the two Ig domains D1-D2.

[0133] According to specific embodiments, the extracellular binding domain of CD64 comprises SEQ ID NO: 6 or 7.

[0134] According to specific embodiments, the extracellular binding domain of CD64 consists of SEQ ID NO: 6 or 7.

[0135] According to specific embodiments, the term “extracellular binding domain of CD64” also encompasses functional homologues or fragments, which exhibit the desired activity (z.e., binding an IgG Fc domain).

[0136] The homolog of any of the polypeptides or proteins disclosed herein can be, for example, at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, at least 85 %, at least 90 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptide sequence provided herein or a functional fragment thereof which exhibit the desired activity as defined herein; or at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, at least 85 %, at least 90 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical to the polynucleotide sequence encoding same.

[0137] Sequence identity or homology can be determined using any protein or nucleic acid sequence alignment algorithm such as Blast, ClustalW, and MUSCLE.

[0138] The homolog may also refer to an ortholog, a deletion, insertion, or substitution variant, including a conservative and non-conservative amino acid substitution, as further described hereinbelow.

[0139] The term "amino acid" or "amino acids" is understood to include the 20 naturally occurring amino acids; those amino acids often modified post-translationally in vivo, including, for example, hydroxyproline, phosphoserine and phospho threonine; and other unusual amino acids including, but not limited to, 2-aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine. Furthermore, the term "amino acid" includes both D- and L-amino acids.

[0140] According to specific embodiments, the amino acid sequences described herein may comprise conservative and / or non-conservative amino acid substitutions.

[0141] The term “conservative substitution” as used herein, refers to the replacement of an amino acid present in the native sequence in the peptide with a naturally or non-naturally occurring amino or a peptidomimetics having similar steric properties. Where the side-chain of the native amino acid to be replaced is either polar or hydrophobic, the conservative substitution should be with a naturally occurring amino acid, a non-naturally occurring amino acid or with a peptidomimetic moiety which is also polar or hydrophobic (in addition to having the same steric properties as the side-chain of the replaced amino acid).

[0142] As naturally occurring amino acids are typically grouped according to their properties, conservative substitutions by naturally occurring amino acids can be easily determined bearing in mind the fact that in accordance with the invention replacement of charged amino acids by sterically similar non-charged amino acids are considered as conservative substitutions.

[0143] For producing conservative substitutions by non-naturally occurring amino acids it is also possible to use amino acid analogs (synthetic amino acids) well known in the art. A peptidomimetic of the naturally occurring amino acid is well documented in the literature known to the skilled practitioner. When performing conservative substitutions the substituting amino acid should have the same or a similar functional group in the side chain as the original amino acid.

[0144] The phrase "non-conservative substitutions" as used herein refers to replacement of the amino acid as present in the parent sequence by another naturally or non-naturally occurring amino acid, having different electrochemical and / or steric properties. Thus, the side chain of the substituting amino acid can be significantly larger (or smaller) than the side chain of the native amino acid being substituted and / or can have functional groups with significantly different electronic properties than the amino acid being substituted. Examples of non-conservative substitutions of this type include the substitution of phenylalanine or cycohexylmethyl glycine for alanine, isoleucine for glycine, or -NH-CH[(-CH2)5-COOH]-CO- for aspartic acid.

[0145] As mentioned, the receptor or the protein complex comprises an intracellular signaling domain, such that upon binding of the extracellular binding domain to the Fc domain the signaling is transmitted in the immune cell.

[0146] Such intracellular signaling domains are well known in the art, and are further described herein.

[0147] According to specific embodiments, the intracellular signaling domain transmits an activation signal.

[0148] According to specific embodiments, the intracellular signaling domain comprises an immunoreceptor tyrosine-based activation motif (IT AM).

[0149] As used herein, the terms “activating” or "activation" refer to the process of stimulating a T cell that results in cellular proliferation, maturation, cytokine production, chemotaxis and / or induction of effector functions.

[0150] Methods of determining signaling of an activating signal are well known in the art, and include, but are not limited to, enzymatic activity assays such as kinase activity assays, and expression of molecules involved in the signaling cascade using e.g. PCR, Western blot, immunoprecipitation and immunohistochemistry. Additionally or alternatively, determining transmission of an activating signal can be effected by evaluating T cell activation or function. Methods of evaluating T cell activation or function are well known in the art and include, but are not limited to, proliferation assays such as CFSE staining, MTT, Alamar blue, BRDU and thymidine incorporation, cytotoxicity assays such as CFSE staining, chromium release, Calcin AM, cytokine secretion assays such as intracellular cytokine staining, EEISPOT and EEISA, expression of activation markers such as CD25, CD69, CD137, CD107a, PD1, and CD62L using flow cytometry. Non-limiting examples of intracellular signaling domain that can be used with specific embodiments of the invention include the signaling domains of CD3^, FcRy, DAP 12, DAP 10, FcsRip, FcsRIy, CD79, or a functional fragment or homologue thereof.

[0151] As used herein, the term “CD3 ’, also known as CD247, refers to the polypeptide expression product of the CD247 gene (corresponding to human Gene ID 919). According to specific embodiments, CD3(^ is human CD3(^. According to a specific embodiment, the CD3(^ protein refers to the human protein, such as provided in the following GenBank Numbers NP_000725 and / or NP_932170 (SEQ ID NO: 8).

[0152] A non-limiting example of an intracellular domain of CD3(^ comprises SEQ ID NO: 9.

[0153] As used herein the phrase “Fc receptor common y chain” abbreviated as “FcRy” refers to the polypeptide expression product of the FCER1G gene (corresponding to human Gene ID 2207). According to specific embodiments, FcRy is human FcRy. According to a specific embodiment, the FcRy protein refers to the human protein, such as provided in the following GenBank Number NP_004097 or UniProt No. P30273 (SEQ ID NO: 10).

[0154] A non-limiting example of an intracellular domain of FcRy comprises amino acids 45-86 corresponding to SEQ ID NO: 10.

[0155] As used herein the term “DAP12”, also known as “TYRO protein tyrosine kinase-binding protein” refers to the polypeptide expression product of the TYROBP gene (corresponding to human Gene ID 7305). According to specific embodiments, DAP12 is human DAP12. According to a specific embodiment, the DAP 12 protein refers to the human protein, such as provided in the following GenBank Number NP_001166985, NP_001166986, NP_003323, NP_937758 or UniProt No. 043914 (SEQ ID NOs: 2-3).

[0156] A non-limiting example of an intracellular domain of DAP 12 comprises amino acids 62- 113 corresponding to SEQ ID NO: 11.

[0157] As used herein the term “DAP10”, also known as “Hematopoietic cell signal transducer” refers to the polypeptide expression product of the HCST gene (corresponding to human Gene ID 10870). According to specific embodiments, DAP10 is human DAP10. According to a specific embodiment, the DAP 10 protein refers to the human protein, such as provided in the following GenBank Number NP_001007470, NP_055081 or UniProt No. Q9UBK5 (SEQ ID NOs: 4-5).

[0158] A non-limiting example of an intracellular domain of DAP 10 comprises amino acids 70- 93 corresponding to SEQ ID NO: 12.

[0159] According to specific embodiments, the receptor and / or the protein complex can comprise a co-stimulatory signaling domain. According to other specific embodiments, the receptor and / or the protein complex does not comprise a co-stimulatory signaling domain.

[0160] As used herein, the phrase “co-stimulatory signaling domain” refers to an amino acid sequence of a co-stimulatory molecule capable of transmitting a secondary stimulatory signal resulting in activation of an immune cell (e.g. T cell). Typically, a co-stimulatory signaling domain does not comprise an IT AM domain.

[0161] Any known co-stimulatory signaling domain can be used with specific embodiments of the present invention. Non-limiting examples of co-stimulatory signaling domains include the signaling domains of 4-1BB, CD28, 0X40, ICOS, CD27, GITR, HVEM, TIM1, LFAl(CDl la), CD2 or a functional fragment or homologue thereof.

[0162] According to specific embodiments, the receptor and / or the protein complex can comprise a cytokine receptor signaling domain.

[0163] According to other specific embodiments, the receptor and / or protein complex does not comprise a cytokine receptor signaling domain.

[0164] As used herein, the phrase “cytokine receptor signaling domain” refers to an amino acid sequence of a cytokine receptor capable of transmitting a stimulatory signal resulting in activation of the T cell.

[0165] Any known cytokine receptor signaling domain can be used with specific embodiments of the present invention. Non-limiting examples of cytokine receptor signaling domains include IL2rg that is the IL2 receptor common gamma chain, the Toll / ILl receptor homology domain (TIR) that is the signaling domain of the myd88 receptor, TNF receptor intracellular domain, IL12-RM intracellular domain, IL12-RM intracellular domain, IL23 receptor intracellular domain, IFNy receptor 1 intracellular domain, IFNy receptor 2 intracellular domain, IL2Rb intracellular domain, IL1 receptor intracellular domain, ILlAcP receptor intracellular domain, or a functional fragment or homologue thereof.

[0166] As the receptor and / or protein complex is typically bound to the cell surface (or membrane), specific embodiments contemplate it further comprises a membrane domain (or transmembrane domain, the two terms are interchangeably used herein). The membrane domain may be endogenous or heterologous to the extracellular and / or intracellular domain. Thus, any known co-stimulatory signaling domain can be used with specific embodiments of the present invention. Non-limiting examples of membrane domains that can be used with specific embodiments of the invention include the membrane domains of an Fc receptor, FcRy, DAP 12, DAP10, CD8 (e.g. CD8a), CD28, or a functional fragment or homologue thereof. According to specific embodiments, the receptor or any of the proteins in the protein complex comprises a dimerizing moiety.

[0167] As used herein, the term “dimerizing moiety” refers to an amino acid sequence capable of forming a polypeptide dimer. Such an amino acid may include for example an amino acid sequence comprising at least two cysteine residues enabling the formation of a disulfide bond between the thiol groups. Methods of determining dimerization are known in the art, including but not limited to immunoprecipitation, size exclusion chromatography, fast protein liquid chromatography (FPLC), multi-angle light scattering (SEC-MALS) analysis, SDS-PAGE analysis, nano-DSF, yeast two-hybrid system (e.g. RRS) and flow cytometry.

[0168] It will be appreciated that the dimerizing moiety of some embodiments of the invention is also capable of forming multimers (e.g., at least three).

[0169] Any known dimerizing moiety known in the art can be used with specific embodiments of the invention.

[0170] Any known dimerizing moiety known in the art can be used with specific embodiments of the invention, including, but not limited to, a dimeric domain (e.g. being part of a transmembrane and / or cytoplasmic domain) of any dimeric protein. According to specific embodiments, the dimerizing moiety comprises an amino acid sequence of the membrane (or transmembrane, the two terms are interchangeably used herein) domain of a co-receptor.

[0171] According to specific embodiments, the Fc-receptor mediated immune cell therapy comprises an immune cell expressing a receptor and a co-receptor, i.e. a protein complex.

[0172] According to a specific embodiment, the Fc-mediated immune cell therapy comprises an immune cell expressing a receptor and a co-receptor, wherein the co-receptor comprises an intracellular signaling domain, and the receptor comprises an extracellular binding domain of an Fc receptor capable of binding said Fc domain and an amino acid sequence capable of recruiting the co-receptor, such that upon binding of the extracellular binding domain to the Fc domain the signaling is transmitted in the immune cell.

[0173] As used herein the term “co-receptor” refers to a cell surface receptor devoid of an extracellular binding domain and comprising an intracellular signaling domain, which is recruited to a primary receptor comprising an extracellular binding domain upon binding of the extracellular binding domain to its target; to thereby transmit the intracellular signal following recognition of a target in a cell expressing both receptors.

[0174] As used herein, the phrase “co-receptor comprising an intracellular signaling domain” refers to full length co-receptor or a fragment thereof or a homolog thereof which comprises an intracellular domain and maintains at least the capability of transmitting an activating signal in a cell expressing the corresponding receptor (the chimeric receptor disclosed herein) upon binding to its target.

[0175] According to specific embodiments, the co-receptor comprises a full length co-receptor.

[0176] According to specific embodiments, the co-receptor comprises a fragment thereof or a homolog thereof which comprises at least the intracellular signaling domain.

[0177] According to specific embodiments, the co-receptor comprises a fragment thereof or a homolog thereof which comprises at least the intracellular signaling domain and the membrane domain.

[0178] Non-limiting examples of co-receptors that can be used with specific embodiments of the invention include FcRy, DAP12, DAP10, FcsRip, FcsRIy, or a functional fragment or homologue thereof.

[0179] According to specific embodiments, the co-receptor is FcRy.

[0180] According to specific embodiments, the co-receptor is DAP12 or DAP10.

[0181] According to specific embodiments, the co-receptor is capable of forming a dimer. The dimer may be a homodimer or a heterodimer.

[0182] According to specific embodiments, the dimer is a homodimer.

[0183] Thus, according to specific embodiments, the co-receptor comprises a dimerizing moiety.

[0184] According to a specific embodiment, the co-receptor comprises a dimerizing moiety such that the co-receptor is expressed in the cell as a homodimer.

[0185] According to specific embodiments, the primary receptor also comprises the intracellular domain of the co-receptor. Under this scenario, when the co-receptor is expressed as a dimer, upon binding of a target to the extracellular binding domain a complex comprising at least three polypeptides (or trimer) each comprising the intracellular signaling domain is formed.

[0186] According to specific embodiments, any of the proteins comprised in the protein complex may comprise an amino acid sequence capable of recruiting the other proteins.

[0187] Thus, according to specific embodiments, the receptor comprises an amino acid sequence capable of recruiting the co-receptor.

[0188] Such recruitment will form a complex upon binding of the extracellular binding domain to the Fc domain, enabling transmission of an intracellular signal in a cell expressing the complex. Methods of determining recruitment of the polypeptides are well known in the art, and include, but are not limited to, enzymatic activity assays such as kinase activity assays, and expression of molecules involved in the signaling cascade using e.g. PCR, Western blot, immunoprecipitation and immunohistochemistry. Additionally or alternatively, determining recruitment of the polypeptides can be effected by evaluating cell activation or function by methods well known in the art such as, but not limited to proliferation assays such as CFSE staining, MTT, Alamar blue, BRDU and thymidine incorporation, cytotoxicity assays such as CFSE staining, chromium release, Calcin AM, and the like. Exemplary methods for determining recruitment are disclosed in e.g. in Kim, M. K., et al. (2003) Blood 101(11): 4479-4484; and Harrison, P. T., et al. (1995) Mol Membr Biol 12(4): 309-312, the contents of which are fully incorporated herein by reference.

[0189] According to a specific embodiment, the recruitment refers to oligomerization e.g., trimerization of polypeptides being part of the protein complex.

[0190] According to specific embodiments, recruiting sequence is heterologous to the receptor or protein.

[0191] According to specific embodiments, the recruiting sequence directly recruits the coreceptor (i.e. without an intermediate polypeptide).

[0192] Such amino acid sequences are well known to the skilled in the art and include, but not limited to amino acid sequences (e.g. the membrane and / or cytoplasmic domain) of proteins such as CD64, CD16, FcsRI and FcaRI, Dectin-2, Mincle, MCL, BDCA-2, ILT7, Glycoprotein VI, NKp30, NKp46, OSCAR, IL71, IREM-3, CD300b, CD300c, TREM-1, TREM-2, CD300e, IRME-2, Siglec-14, NKG2D, MDL-1, Pilr-b, Sirp-bl, NKp44, NKG2C, CD94, or functional fragment or homologue thereof.

[0193] According to specific embodiments, the recruiting sequence is of an Fc receptor.

[0194] According to specific embodiments, the recruiting sequence is of CD64.

[0195] Selection of the recruiting sequence depends on the co-receptor selected and is well within the capabilities of the skilled in the art.

[0196] A non-limiting example of a protein complex that can be used with specific embodiments of the present invention comprises a receptor comprising the extracellular and transmembrane domains of FcyRI fused to the intracellular domain of FcRy (SEQ ID NO: 13) and a co-receptor comprising FcRy (SEQ ID NO: 10).

[0197] Another non-limiting example of a protein complex that can be used with specific embodiments of the present invention comprises a receptor comprising the extracellular and transmembrane domains of FcyRI (SEQ ID NO: 23) and a co-receptor comprising FcRy (SEQ ID NO: 10).

[0198] Any of the components comprised in a single polypeptide as described herein may be linked to each other directly of via a linker, each possibility represents a separate embodiment of the present invention.

[0199] Any linker known in the art can be used with specific embodiments of the invention. According to specific embodiments, the linker may be derived from naturally-occurring multi-domain proteins or is an empirical linker as described, for example, in Chichili et al., (2013), Protein Sci. 22(2): 153-167, Chen et al, (2013), Adv Drug Deliv Rev. 65(10): 1357-1369, the entire contents of which are hereby incorporated by reference. In some embodiments, the linker may be designed using linker designing databases and computer programs such as those described in Chen et al., (2013), Adv Drug Deliv Rev. 65(10): 1357-1369 and Crasto et al., (2000), Protein Eng. 13(5):309-312, the entire contents of which are hereby incorporated by reference.

[0200] According to specific embodiments, the linker is a synthetic linker.

[0201] According to specific embodiments, the linker is a polypeptide.

[0202] Non-limiting examples of linkers that can be used include AS, GS, (GGGGS)n(n=l-4) (SEQ ID NO: 16), GGGGSGGGG (SEQ ID NO: 17), (Gly)s (SEQ ID NO: 18), (Gly)6(SEQ ID NO: 19), (EAAAK)n (n=l-3) (SEQ ID NO: 20), PAPAP (SEQ ID NO: 21), GGGGSGGGGSGGGGS (SEQ ID NO: 22)

[0203] Non-limiting Examples of immune cells that can be used with specific embodiments of the invention include T cells, NK cells, B cells, dendritic cells, macrophages, monocytes and granulocytes, as further described hereinbelow.

[0204] According to specific embodiments, the immune cell is selected from the group consisting of T cells and NK cells.

[0205] The immune cells used according to specific embodiments of the present invention may be autologous or non- autologous; they can be syngeneic or non- syngeneic: allogeneic or xenogeneic to the subject; each possibility represents a separate embodiment of the present invention.

[0206] According to specific embodiments, the cells are autologous to the subject.

[0207] According to specific embodiments, the cells are non-autologous to the subject.

[0208] According to specific embodiments, the immune cell is of a healthy subject.

[0209] According to specific embodiments, the immune cell is of a subject suffering from a pathology (e.g. cancer).

[0210] According to specific embodiments, the immune cell is a healthy (i.e. non-pathological) cell obtained from a subject suffering from a pathology (e.g. cancer).

[0211] According to specific embodiments, the cell is a human cell.

[0212] Methods of obtaining immune cells are well known in the art. Thus, for examples, PBMCs can be isolated by drawing whole blood from a subject and collection in a container containing an anti-coagulant (e.g. heparin or citrate); and apheresis. According to other specific embodiments, the immune cells are obtained from a tissue comprising cells associated with a pathology. Methods for obtaining a tissue sample from a subject are well known in the art and include e.g. biopsy, surgery or necropsy and preparing a single cell suspension thereof. Following, according to specific embodiments, at least one type of an immune cell is purified from the peripheral blood or from the single cell suspension. There are several methods and reagents known to those skilled in the art for purifying immune cells such as leukapheresis, sedimentation, density gradient centrifugation (e.g. ficoll), centrifugal elutriation, fractionation, chemical lysis of e.g. red blood cells (e.g. by ACK), selection of specific cell types using cell surface markers (using e.g. FACS sorter or magnetic cell separation techniques such as are commercially available e.g. from Invitrogen, Stemcell Technologies, Cellpro, Advanced Magnetics, or Miltenyi Biotec.), and depletion of specific cell types by methods such as eradication (e.g. killing) with specific antibodies or by affinity based purification based on negative selection (using e.g. magnetic cell separation techniques, FACS sorter and / or capture ELISA labeling). Such methods are described for example in THE HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, Volumes 1 to 4, (D.N. Weir, editor) and FLOW CYTOMETRY AND CELL SORTING (A. Radbruch, editor, Springer Verlag, 2000).

[0213] According to specific embodiments, the immune cell is a T cell.

[0214] As used herein, the term “T cell” includes CD4+, CD8+ and NKT cells. According to specific embodiments, the T cell expresses CD3.

[0215] According to specific embodiments, the T cell is an effector cell.

[0216] As used herein, the term “effector T cell” refers to a T cell that activates or directs other immune cells e.g. by producing cytokines or has a cytotoxic activity e.g., CD4+, Thl / Th2, CD8+ cytotoxic T lymphocyte.

[0217] According to specific embodiments, the T cell is a CD4+ T cell.

[0218] According to other specific embodiments, the T cell is a CD8+ T cell.

[0219] According to specific embodiments, the T cell is a aP T cell. According to specific embodiments, the T cell is a y6 T cell. According to specific embodiments, the T cell is a naive T cell.

[0220] According to a specific embodiments, the T cell has a CD45RAhighCCR7highCD27highCD45ROIlltCD62Llow’illtphenotype.

[0221] According to specific embodiments, the T cell is a memory T cell. Non-limiting examples of memory T cells include effector memory and central memory cells. Effector memory cells typically have a CD3+, CD4+ / CD8+, CD45ROhigh, CD45RAlow, CCR7low, CD62Llow, CD27low-1Iltphenotype while central memory cells typically have a CD3+, CD4+ / CD8+, CD45ROhigh, CD45RAlow, CCR7high, CD62Lhigh, CD27high.

[0222] According to specific embodiments, the T cell is a proliferating cell.

[0223] As used herein, the phrase ’’proliferating cell” refers to a T cell that proliferates upon stimulation as defined by a cell proliferation assay, such as, but not limited to, CFSE staining, MTS, Alamar blue, BRDU, thymidine incorporation, and the like.

[0224] According to specific embodiments, the T cell is a proliferating CD4+ T cell.

[0225] According to specific embodiments, the T cell is a proliferating CD8+ T cell.

[0226] According to specific embodiments, the T cell is an NKT cell.

[0227] As used herein the term “NKT cell” refers to a specialized T cell that express a variety of molecular markers that are typically associated with NK cells, such as NK1.1. NKT cells include NK1.1+ and NK1.1-, as well as CD4+, CD4-, CD8+ and CD8- cells.

[0228] According to other specific embodiments, the T cells is not an NKT cell.

[0229] According to specific embodiments, the T cell expresses an endogenous T cell receptor (TCR).

[0230] According to other specific embodiments, the T cell does not express an endogenous TCR.

[0231] According to specific embodiments, the T cell is expressing a TCR specific for a pathological (diseased, e.g. cancerous) cell, i.e. recognizes an antigen presented in the context of MHC which is overexpressed or only expressed by a pathologic cell as compared to a non- pathologic cell. Non-limiting examples of cancer antigens are further described hereinbelow.

[0232] According to specific embodiments, the T cell is endogenously expressing a TCR specific for a pathological cell (e.g. cancerous cell).

[0233] According to specific embodiments, the T cell expresses a recombinant TCR specific for a pathologic cell (e.g. cancerous cell), as further described hereinbelow.

[0234] According to specific embodiments, the immune cells comprise NK cells.

[0235] As used herein, the term “NK cells” refers to differentiated lymphocytes with a CD 16+ CD56+ and / or CD57+ TCR- phenotype. NK are characterized by their ability to bind to and kill cells that fail to express “self’ MHC / HLA antigens by the activation of specific cytolytic enzymes, the ability to kill tumor cells or other diseased cells that express a ligand for NK activating receptors, and the ability to release protein molecules called cytokines that stimulate or inhibit the immune response.

[0236] According to specific embodiments, the immune cells comprise B cells. As used herein the term “B cells” refers to a lymphocyte with a B cell receptor (BCR)+, CD 19+ and or B220+ phenotype. B cells are characterized by their ability to bind a specific antigen and elicit a humoral response.

[0237] According to specific embodiments, the immune cells comprise phagocytic cells.

[0238] As used herein, the term “phagocytic cells” refer to a cell that is capable of phagocytosis and include both professional and non-professional phagocytic cells. Methods of analyzing phagocytosis are well known in the art and include for examples killing assays, flow cytometry and / or microscopic evaluation (live cell imaging, fluorescence microscopy, confocal microscopy, electron microscopy). According to specific embodiments, the phagocytic cells are selected from the group consisting of monocytes, dendritic cells (DCs) and granulocytes.

[0239] According to specific embodiments, the immune cells comprise monocytes.

[0240] According to specific embodiments, the term “monocytes” refers to both circulating monocytes and to macrophages (also referred to as mononuclear phagocytes) present in a tissue.

[0241] According to specific embodiments, the monocytes comprise macrophages. Typically, cell surface phenotype of macrophages include CD 14, CD40, CD 11b, CD64, F4 / 80 (mice) / EMRl (human), lysozyme M, MAC-l / MAC-3 and CD68.

[0242] According to specific embodiments, the monocytes comprise circulating monocytes. Typically, cell surface phenotypes of circulating monocytes include CD14 and CD16 (e.g. CD14++ CD16-, CD14+CD16++, CD14++CD16+).

[0243] According to specific embodiments, the immune cells comprise DCs.

[0244] As used herein the term “dendritic cells (DCs)” refers to any member of a diverse population of morphologically similar cell types found in lymphoid or non-lymphoid tissues. DCs are a class of professional antigen presenting cells, and have a high capacity for sensitizing HLA-restricted T cells. DCs include, for example, plasmacytoid dendritic cells, myeloid dendritic cells (including immature and mature dendritic cells), Langerhans cells, interdigitating cells, follicular dendritic cells. Dendritic cells may be recognized by function, or by phenotype, particularly by cell surface phenotype. These cells are characterized by their distinctive morphology having veil-like projections on the cell surface, intermediate to high levels of surface HLA-class II expression and ability to present antigen to T cells, particularly to naive T cells (See Steinman R, et al., Ann. Rev. Immunol. 1991; 9:271-196.). Typically, cell surface phenotype of DCs include CDla+, CD4+, CD86+, or HLA-DR. The term DCs encompasses both immature and mature DCs.

[0245] According to specific embodiments, the immune cells comprise granulocytes. As used herein, the tern “granulocytes” refer to polymorphonuclear leukocytes characterized by the presence of granules in their cytoplasm.

[0246] According to specific embodiments, the granulocytes comprise neutrophils.

[0247] According to specific embodiments, the granulocytes comprise mast-cells.

[0248] According to specific embodiments, the immune cell is also transduced to express a recombinant immune cell activation receptor or protein complex other than the Fc-binding receptor or complex. Such receptors and complexes are known in the art and include, but not limited to, a TCR or a chimeric antigen receptor (CAR) having specificity to a pathological cell.

[0249] The methods and uses disclosed herein comprise administering to the subject a therapeutic composition comprising an Fc domain and having specificity to a pathological cell.

[0250] As used herein, the phrase “having specificity to a pathological cell” refers to a moiety (e.g. an antibody binding domain, a ligand, a receptor, a leptin etc.) having a binding affinity (e.g. below 10’4nM) to a pathological cell (i.e. to an antigen overexpressed or only expressed by pathological cells as compared to non-pathological cells). Assays for testing binding are well known in the art and are further described herein. According to specific embodiments, specificity is mediated by CDR’s being specific to an antigen presented by the pathological cell.

[0251] Therapeutic compositions comprising Fc domains specific for pathological cells are well known in the art and include, but not limited to, Fc-fusion proteins and antibodies.

[0252] According to specific embodiments, the methods and uses disclosed herein are effected in the absence of the Fc-mediated immune cell therapy. However, it will be appreciated that the Fc domain of the therapeutic composition is selected such that it is capable of binding the Fc binding moiety of the Fc-mediated immune cell therapy previously administered to the subject.

[0253] According to specific embodiments, the Fc domain is of an IgG or IgM antibody.

[0254] According to specific embodiments, the Fc domain is of an IgG antibody (e.g. IgGl, IgG2, IgG3, IgG4).

[0255] According to specific embodiments, the therapeutic composition is an Fc-fusion protein.

[0256] As used herein the term, “Fc-fusion protein” refers to a molecule comprising an amino acid sequence capable of binding a pathological cell (i.e. an antigen overexpressed or only expressed on a pathological cell) combined with an Fc domain of an antibody.

[0257] Selection of the Fc-fusion protein used is well within the capability of those skilled in the art, and depends on the type of the medical condition and the antigens expressed by the pathological cells associated with the pathology.

[0258] Non-limiting examples of Fc-fusion proteins that can be used with specific embodiments are disclosed in Weidle et al. Cancer Genomics and Proteomics (2012) 9(6): 357-372; and Sioud et al. Molecular Therapy - Methods & Clinical Development (2015) 2, 15043, the contents of which are fully incorporated herein by reference.

[0259] According to specific embodiments, the therapeutic composition is an antibody.

[0260] The term "antibody" as used in this invention includes intact molecules as well as functional fragments thereof (that are capable of binding to an epitope of an antigen).

[0261] As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

[0262] According to specific embodiments, the antibody is a whole or intact antibody.

[0263] According to specific embodiments, the antibody comprises an Fc domain.

[0264] According to specific embodiments, the antibody is an antibody fragment.

[0265] According to a specific embodiment, the antibody fragments include, but are not limited to, single chain, Fab, Fab’ and F(ab')2 fragments, Fd, Fcab, Fv, dsFv, scFvs, diabodies, minibodies, nanobodies, Fab expression library or single domain molecules such as VH and VE that are capable of binding to an epitope of the antigen in an HEA restricted manner.

[0266] Suitable antibody fragments for practicing some embodiments of the invention include a complementarity-determining region (CDR) of an immunoglobulin light chain (referred to herein as “light chain”), a complementarity-determining region of an immunoglobulin heavy chain (referred to herein as “heavy chain”), a variable region of a light chain, a variable region of a heavy chain, a light chain, a heavy chain, an Fd fragment, and antibody fragments comprising essentially whole variable regions of both light and heavy chains such as an Fv, a single chain Fv (scFv), a disulfide-stabilized Fv (dsFv), an Fab, an Fab’, and an F(ab’)2, or antibody fragments comprising the Fc region of an antibody.

[0267] According to specific embodiments, the identity of the amino acid residues in the antibody that make up the variable region and / or the CDRs is determined by the method of Kabat et al. (See, e.g., Kabat et al., 1992, Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, NIH, Washington D.C.).

[0268] Functional antibody fragments comprising whole or essentially whole variable regions of both light and heavy chains are defined as follows:

[0269] (i) Fv, defined as a genetically engineered fragment consisting of the variable region of the light chain (VL) and the variable region of the heavy chain (VH) expressed as two chains; (ii) single chain Fv (“scFv”), a genetically engineered single chain molecule including the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

[0270] (iii) disulfide- stabilized Fv (“dsFv”), a genetically engineered antibody including the variable region of the light chain and the variable region of the heavy chain, linked by a genetically engineered disulfide bond.

[0271] (iv) Fab, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme papain to yield the intact light chain and the Fd fragment of the heavy chain which consists of the variable and CHI domains thereof;

[0272] (v) Fab’, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin, followed by reduction (two Fab’ fragments are obtained per antibody molecule);

[0273] (vi) F(ab’)2, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin (i.e., a dimer of Fab’ fragments held together by two disulfide bonds);

[0274] (vii) Single domain antibodies or nanobodies are composed of a single VH or VL domains which exhibit sufficient affinity to the antigen; and

[0275] (viii) Fcab, a fragment of an antibody molecule containing the Fc portion of an antibody developed as an antigen-binding domain by introducing antigen-binding ability into the Fc region of the antibody.

[0276] Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).

[0277] It will be appreciated that for human therapy, humanized antibodies are preferably used.

[0278] According to specific embodiments, the antibody is a humanized antibody. Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab').sub.2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non- human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323- 329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

[0279] Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[0280] According to specific embodiments, the antibody is a human antibody.

[0281] Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(l):86-95 (1991)]. Similarly, human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio / Technology 10,: 779- 783 (1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995).

[0282] Selection of the therapeutic antibody used is well within the capability of those skilled in the art, and depends on the type of the disease and the antigens expressed by the pathological cells associated with the pathology.

[0283] According to specific embodiments, the antibody binds an antigen overexpressed or only expressed by a pathological cell e.g. cancerous cell.

[0284] Non-limiting examples for known cancer antigens include MAGE-AI, MAGE-A2, MAGE- A3, MAGE-A4, MAGE-AS, MAGE-A6, MAGE-A7, MAGE-AS, MAGE-A9, MAGE- AIO, MAGE-A11, MAGE-A12, GAGE-I, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, B AGE-1, RAGE- 1, LB33 / MUM-1, PRAME, NAG, MAGE-Xp2 (MAGE- B2), MAGE-Xp3 (MAGE-B3), MAGE-Xp4 (MAGE-B4), MAGE- C1 / CT7, MAGE-C2, NY- ESO-1, LAGE-1, SSX-1, SSX-2(HOM-MEL-40), SSX-3, SSX-4, SSX-5, SCP-1 and XAGE, melanocyte differentiation antigens, p53, ras, CEA, MUCI, PMSA, PSA, tyrosinase, Melan-A, MART-I, gplOO, gp75, alphaactinin-4, Bcr-Abl fusion protein, Casp-8, beta-catenin, cdc27, cdk4, cdkn2a, coa-1, dek-can fusion protein, EF2, ETV6-AML1 fusion protein, LDLR- fucosyltransferaseAS fusion protein, HLA-A2, HLA-A11, hsp70-2, KIAA0205, Mart2, Mum-2, and 3, neo-PAP, myosin class I, OS-9, pml-RAR alpha fusion protein, PTPRK, K-ras, N-ras, Triosephosphate isomerase, GnTV, Herv-K-mel, NA-88, SP17, and TRP2-Int2, (MART-I), E2A- PRL, H4-RET, IGH-IGK, MYL-RAR, Epstein Barr virus antigens, EBNA, human papillomavirus (HPV) antigens E6 and E7, TSP- 180, MAGE-4, MAGE-5, MAGE-6, pl85erbB2, plSOerbB-3, c-met, nm-23Hl, PSA, TAG-72-4, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, alpha.-fetoprotein, 13HCG, BCA225, BTAA, CA 125, CA 15-3 (CA 27.29VBCAA), CA 195, CA 242, CA-50, CAM43, CD68\KP1, CO-029, FGF-5, 0250, Ga733 (EpCAM), HTgp-175, M344, MA-50, MG7-Ag, M0V18, NBM70K, NYCO-I, RCASI, SDCCAG16, TA-90 (Mac-2 binding protein\cyclophilin C-associated protein), TAAL6, TAG72, TLP, TPS, tyrosinase related proteins, TRP-1, or TRP-2.

[0285] According to specific embodiments, the antibody binds CD20, HER2, EGFR, TRP-1, CD44, PDL-1, MUC-1, MUC-16, CEA or EpCAM.

[0286] According to specific embodiments, the antibody is an IgG antibody (e.g. IgGl, IgG2, IgG3, IgG4).

[0287] According to a specific embodiment, the antibody isotype is IgGl or IgG3. According to specific embodiments, the therapeutic antibody is an anti-CD20 or an anti- HER2 antibody.

[0288] According to some embodiments of the invention, the therapeutic antibody is selected from the group consisting of Atezolizumab, Avelumab, Alemtuzumab, Cetuximab, Panitumumab, Nimotuzumab, Rituximab, Gatipotuzumab (previously known as PankoMab- GEX®), Trastuzumab, Alemtuzumab, Bevacizumab, Ofatumumab, Pertuzumab, ofatumumab, obinutuzumab and IVIG.

[0289] According to specific embodiments, the therapeutic antibody is selected from the group consisting of Rituximab and Trastuzumab.

[0290] It will be appreciated that according to specific embodiments, the previous treatment with the Fc-mediated immune cell therapy further comprised a therapeutic composition comprising an Fc domain and having specificity to a pathological cell.

[0291] Under this scenario, the therapeutic composition currently administered by the methods and uses disclosed herein and the therapeutic composition administered in the previous treatment may have the same or distinct specificities.

[0292] Thus, according to specific embodiments, the therapeutic composition currently administered by the methods and uses disclosed herein and the therapeutic composition administered in the previous treatment comprise the same specificity.

[0293] According to other specific embodiments, the therapeutic composition currently administered by the methods and uses disclosed herein has a specificity distinct from the therapeutic composition administered in the previous treatment.

[0294] The therapeutic compositions disclosed herein can be administered to the subject per se, or in a pharmaceutical composition where it is mixed with suitable carriers or excipients.

[0295] As used herein a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

[0296] Herein the term "active ingredient" refers to the therapeutic composition accountable for the biological effect.

[0297] Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases. Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

[0298] Techniques for formulation and administration of drugs may be found in “Remington’s Pharmaceutical Sciences,” Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.

[0299] Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, intradermal, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, intraperitoneal, intranasal, or intraocular injections.

[0300] Conventional approaches for drug delivery to the central nervous system (CNS) include: neurosurgical strategies (e.g., intracerebral injection or intracerebro ventricular infusion); molecular manipulation of the agent (e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB) in an attempt to exploit one of the endogenous transport pathways of the BBB; pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers); and the transitory disruption of the integrity of the BBB by hyperosmotic disruption (resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide). However, each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possible risk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.

[0301] Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a patient.

[0302] Pharmaceutical compositions of some embodiments of the invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

[0303] Pharmaceutical compositions for use in accordance with some embodiments of the invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

[0304] For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0305] For oral administration, the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and / or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0306] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0307] Pharmaceutical compositions which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.

[0308] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0309] For administration by nasal inhalation, the active ingredients for use according to some embodiments of the invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0310] The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents.

[0311] Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.

[0312] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.

[0313] The pharmaceutical composition of some embodiments of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides. Alternative embodiments include depots providing sustained release or prolonged duration of activity of the active ingredient in the subject, as are well known in the art.

[0314] Pharmaceutical compositions suitable for use in context of some embodiments of the invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., cancer) or prolong the survival of the subject being treated.

[0315] Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

[0316] For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.

[0317] Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 P-l).

[0318] Dosage amount and interval may be adjusted individually to provide levels of the active ingredient are sufficient to induce or suppress the biological effect (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.

[0319] Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

[0320] The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

[0321] Compositions of some embodiments of the invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.

[0322] According to specific embodiments, any of the genes, polynucleotides, proteins, polypeptides and / or proteinaceous moieties described herein may have a sequence of a human gene, polynucleotide, protein, polypeptide and / or proteinaceous moiety or a functional fragment or homolog thereof which exhibit the desired activity as described herein.

[0323] According to specific embodiments, the gene, polynucleotide, protein, polypeptide and / or proteinaceous moiety is of a human origin.

[0324] According to other specific embodiments, the gene, polynucleotide, protein, polypeptide and / or proteinaceous moiety is a homolog of a human gene, polynucleotide, protein, polypeptide and / or proteinaceous moiety. Such homologues can be, for example, at least 70 %, at least 75 %, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the human sequence.

[0325] As used herein the term “about” refers to ± 10 %

[0326] The terms "comprises", "comprising", "includes", "including", “having” and their conjugates mean "including but not limited to".

[0327] The term “consisting of’ means “including and limited to”.

[0328] The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and / or parts, but only if the additional ingredients, steps and / or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.

[0329] As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof. Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0330] Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging / ranges between” a first indicate number and a second indicate number and “ranging / ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

[0331] As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

[0332] When reference is made to particular sequence listings, such reference is to be understood to also encompass sequences that substantially correspond to its complementary sequence as including minor sequence variations, resulting from, e.g., sequencing errors, cloning errors, or other alterations resulting in base substitution, base deletion or base addition, provided that the frequency of such variations is less than 1 in 50 nucleotides, alternatively, less than 1 in 100 nucleotides, alternatively, less than 1 in 200 nucleotides, alternatively, less than 1 in 500 nucleotides, alternatively, less than 1 in 1000 nucleotides, alternatively, less than 1 in 5,000 nucleotides, alternatively, less than 1 in 10,000 nucleotides.

[0333] Each patent, publication, and non-patent literature cited in the application is hereby incorporated by reference in its entirety as if each was incorporated by reference individually.

[0334] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

[0335] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

[0336] EXAMPLES

[0337] Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.

[0338] Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques.

[0339] EXAMPLE 1

[0340] LONG TERM PRESENCE OF T CELLS RECOMBINANTLY EXPRESSING AN Fey RECEPTOR AND AN FcRy CO-RECEPTOR IN A LYMPHOMA MOUSE MODEL

[0341] Materials and methods:

[0342] Generation of T cells expressing recombinant Fey receptor and an FcR co-receptor - As previously described in International Patent Application Publication No. WO2021 / 260696. Briefly, a construct comprising a nucleic acid sequence SEQ ID NO: 15 encoding the extracellular and transmembrane domains of FcyRI fused to the intracellular domain of FcRy (SEQ ID NO: 13), T2A skipping peptide (SEQ ID NO: 15) and FcRy (SEQ ID NO: 10), denoted herein as Alpha-gamma-2A-gamma (AG2G). The plasmids were packed into retroviruses (pMSGVl plasmid), and used to infect PBMCs from peripheral blood of healthy human donors (CellGeneration). To ensure membrane localization of the constructs, cells were stained for CD3 and CD64 and analyzed by flow cytometer.

[0343] In vivo tumor model - Luciferase-expressing Raji lymphoma cells (BPS Biosystems, #78622) were injected intravenously (i.v.) to NOD / SCID gamma (NSG) mice (Jackson Laboratories) (IxlO6cells / mouse, n=8). The following day, mice were treated with either saline (placebo control), rituximab [administered intraperitonealy (i.p.)] alone or in combination with IxlO7AG2G-expressing T cells (administered i.v. 250 pg / mouse). Thereafter, rituximab (125 pg / mouse) was administered weekly. Mice were followed up for survival, weight and tumor burden by luciferase activity using IVIS imager until dead of until termination of the experiment on day 41. Flow cytometry - Bone marrow cells were extracted from mice at the end of the experiment and stained with Brilliant Violet 421 or PE anti-human CD64 (10.1, BioLegend), FITC-anti-human CD3 (UCH1, BioLegend), Brilliant Violet 421-anti-CD4 (RPA-T4), APC- anti-CD8 (RPA-T8), PE / Cyanine7 anti-human CD45 (HI30, BioLegend), APC anti-human CD45RO (UCHL1, BioLegend), PE anti-human CCR7 (G043H7, BioLegend); and analyzed by a flow cytometer.

[0344] Results:

[0345] T cells recombinantly expressing a receptor comprising the amino acid sequence of CD64 fused to the intracellular domain of FcRy and an FcRy co-receptor, referred to herein as FcgRI-alpha-gamma-2A-Gamma (AG2G), were previously described in International Patent Application Publication No. WO2021 / 260696. These T cells were shown to have anti-tumor activities both in-vitro and in-vivo, only when administrated in combination with a tumorbinding antibody. Further, it was shown that the cells do not secrete IFNy or IL-2 unless they are activated by target cells coated with antibodies.

[0346] The present inventors now examined presence of these cells in the treated mice and if their presence correlated to the anti-tumor effect; and also if these cells acquire a T cell memory phenotype.

[0347] To this end, the AG2G-expressing T cells were administered to a mouse lymphoma tumor model in combination with rituximab. IVIS analysis showed that while saline treated mice developed detectable tumors immediately after tumor cells inoculation; rituximab -treated mice showed detectable tumor mass starting on day 14; and AG2G-expressing T cells + rituximab treated mice, were without detectable tumors at this time point (Figures 1A-B). Mice were imaged by IVIS until day 21, when all the saline treated mice were dead, and all the rituximab treated mice had substantial tumor masses. All the rituximab-treated mice were dead by day 37, while AG2G-expressing T cells + rituximab treated mice showed 100 % survival until day 41 (when they were sacrificed) (Figures 1C-D). Post-mortem histological analyses of the AG2G-expressing T cells + rituximab treated mice showed that 3 out of the 8 mice had tumor cells in the abdominal cavity, while 5 out of 8 were totally cleared from tumor cells. Flow cytometry analysis of bone-marrow cells extracted from the AG2G-expressing T cells + rituximab treated mice showed existence of human T cells, wherein the percentage of cells having a memory phenotype was positively correlated with the anti-tumor activity (Figures 2A- D). Moreover, the percentage of effector memory human T cells was statistically significantly higher in the full responders as compared to the partial responders. EXAMPLE 2

[0348] LONG TERM PRESENCE OF T CELLS RECOMBINANTLY EXPRESSING AN Fey RECEPTOR AND AN FcRy CO-RECEPTOR IN A HER2-EXPRESING GASTRIC CARCINOMA MOUSE MODEL

[0349] Materials and methods:

[0350] Generation of T cells expressing recombinant Fey receptor and an FcRy co-receptor - As described in Example 1 hereinabove.

[0351] In vivo tumor model -NCI-N87 gastric carcinoma cells expressing HER2 (ATCC) were injected subcutaneously (3xl06cells / mouse, n=8) to NSG mice (Jackson Laboratories). When tumors reached ~70 mm3, mice were injected i.v. with a single dose of IxlO7AG2G-transduced T cells in combination with weekly i.p. administrations of trastuzumab (125 pg / mouse). As controls, mice were injected with saline alone (i.v. and i.p.) or in combination (i.v.) with weekly trastuzumab i.p. (125 pg / mouse). Mice were followed for weight, survival, and tumor volume, until day 56 after start of treatment, when they were sacrificed for analysis.

[0352] Flow cytometry - Bone marrow cells were extracted from mice at the end of the experiment (56 days post the start of treatment), and stained for several human markers using FITC-anti-human CD3 (UCH1, BioLegend), Brilliant Violet 421-anti-CD4 (RPA-T4, BioLegend), APC anti-human CD45RO (UCHL1, BioLegend), PE-Cy7 anti-CD45RA (HI100, BioLegend), PE anti-human CCR7 (G043H7, BioLegend), Brilliant Violet 605-anti-CD62L (DREG-56, BioLegend), PE-Cy5 anti-CD27 (0323, BioLegend); and analyzed by flow cytometer.

[0353] Results'.

[0354] Administration of AG2G-expressing T cells + trastuzumab reduced tumor size over time, until almost no tumor mass was detected the end of the experiment (day 56 after treatment), while mice treated with saline alone or in combination with trastuzumab developed tumors with increasing size over time (Figure 4A).

[0355] Flow cytometry analysis of bone-marrow cells extracted from the AG2G-expressing T cells + trastuzumab treated mice showed existence of human T cells that acquired effector memory phenotype, as compared to cultured AG2G-expresing T cells originally used for injection into the mice that had a mixed naive - central memory phenotype (Figures 4B). Specifically, the cells extracted from the bone marrow of AG2G-expresing T cells + trastuzumab treated mice had a CD45ROhigh, CD45RAlow, CCR7low, CD62Llow, CD27low’intphenotype while the cultured AG2G-expresing T cells had a CD45RAhighCCR7highCD27highCD45ROintCD62Llow-intphenotype.

[0356] EXAMPLE 3

[0357] ANTIBODY TREATMENT AS A SECOND LINE THERAPY FOR CANCER IN MICE PREVIOUSELY TREATEED WITH T CELLS RECOMBINANTLY EXPRESSING AN Fey RECEPTOR AND AN FcRy CO-RECEPTOR

[0358] Materials and methods:

[0359] Generation of T cells expressing recombinant Fey receptor and an FcR co-receptor - As described in Example 1 hereinabove.

[0360] In vivo tumor model -NCI-N87 gastric carcinoma cells expressing HER2 (ATCC) were injected subcutaneously (2.5xl06cells / mouse, n=5) to NSG mice (Jackson Laboratories). 13 days following tumor inoculation a single dose of IxlO7of non-transduced or AG2G-transduced T cells was administered i.v. in combination with weekly i.p administration of trastuzumab (250 pg / mouse). On day 85 following tumor inoculation, four mice that were treated with AG2G- expressing T cells + trastuzumab and showed no visible tumors were injected again with NCI- N87 tumor cells (2ndtumor challenge, 3xl06cells / mouse, subcutaneously). As a control, at this time point, four new naive mice were also inoculated with NCI-N87 tumor cells (3xl06cells / mouse, subcutaneously). All 8 mice developed tumors and were treated with trastuzumab (250 pg / mouse i.p.) on days 98 and 112. Mice were followed up for survival, weight and tumor volume by caliper measurement until dead or until termination of the experiment on day 131.

[0361] Flow cytometry - Bone marrow cells were extracted from mice, and stained for several human markers using FITC-anti-human CD3 (UCH1, Bio Legend), APC anti-human CD45RO (UCHL1, BioLegend) and PE anti-human CCR7 (G043H7, BioLegend); and analyzed by flow cytometer.

[0362] Results:

[0363] Administration of AG2G-expressing T cells + trastuzumab completely cleared the tumors in all treated mice, while mice treated with non-transduced T cells + trastuzumab developed tumors with increasing size over time (Figure 3A).

[0364] On day 85 following inoculation of the tumor cells, four mice that were treated with the AG2G-expressing T cells + trastuzumab and showed no visible tumors were re-challenged with the same HER2 positive gastric carcinoma cells (2ndtumor challenge). As a control, at this time point, four new naive mice were also inoculated with the HER2 positive gastric carcinoma cells. All 8 mice developed tumors and were treated with trastuzumab alone. Trastuzumab treatment of the re-challenged mice eradicated the second tumor; while the naive mice developed tumors with increasing size over time (Figure 3A). Importantly, flow cytometry analysis of bone- marrow cells isolated from mice sacrificed on day 131 showed presence of human T cells with effector memory phenotype in the re-challenged mice (Figure 3B).

[0365] Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

[0366] It is the intent of the applicant(s) that all publications, patents and patent applications referred to in this specification are to be incorporated in their entirety by reference into the specification, as if each individual publication, patent or patent application was specifically and individually noted when referenced that it is to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting. In addition, any priority document(s) of this application is / are hereby incorporated herein by reference in its / their entirety.

Claims

WHAT IS CLAIMED IS:

1. A method of treating a medical condition associated with pathological cells in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a therapeutic composition comprising an Fc domain and having specificity to the pathological cells, wherein said subject is non naive to an Fc-mediated immune cell therapy and comprises memory cells of said immune cell therapy in a lymphoid organ sample.

2. A therapeutic composition comprising an Fc domain and having specificity to pathological cells for use in treating a medical condition associated with said pathological cells in a subject in need thereof, wherein said subject is non naive to an Fc-mediated immune cell therapy and comprises memory cells of said immune cell therapy in a lymphoid organ sample.

3. The method of claim 1 or the therapeutic composition for use of claim 2, wherein said medical condition is cancer and said pathological cell is a cancerous cell.

4. The method or the therapeutic composition for use of claim 3, wherein said cancer is a metastatic cancer.

5. The method or the therapeutic composition for use of claim 3, wherein said cancer is a recurred or relapsed cancer.

6. The method or the therapeutic composition for use of claim 3, wherein said cancer has been refractory to previous treatment with said Fc- mediated immune cell therapy.

7. The method or the therapeutic composition for use of any one of claims 1-6, wherein said Fc-mediated immune cell therapy further comprised a therapeutic composition comprising an Fc domain and having specificity to a pathological cell.

8. The method or the therapeutic composition for use of any one of claims 1-7, wherein said therapeutic composition is an Fc-fusion protein.

9. The method or the therapeutic composition for use of any one of claims 1-7, wherein said therapeutic composition is an antibody.

10. The method or the therapeutic composition for use of any one of claims 1-9, wherein said Fc-mediated immune cell therapy comprises an immune cell expressing a receptor or a protein complex having an extracellular antigen binding domain of an antibody specific for said Fc domain.

11. The method or the therapeutic composition for use of any one of claims 1-9, wherein said Fc- mediated immune cell therapy comprises an immune cell expressing a receptor or a protein complex having an extracellular binding domain of an Fc receptor capable of binding said Fc domain.

12. The method or the therapeutic composition for use of any one of claims 1-9, wherein said Fc-mediated immune cell therapy comprises an immune cell expressing a receptor and a co-receptor, wherein said co-receptor comprises an intracellular signaling domain, and said receptor comprises an extracellular binding domain of an Fc receptor capable of binding said Fc domain and an amino acid sequence capable of recruiting said co-receptor, such that upon binding of said extracellular binding domain to said Fc domain said signaling is transmitted in said immune cell.

13. The method or the therapeutic composition for use of claim 12, wherein said receptor further comprises a cytoplasmic domain comprising said intracellular signaling domain of said co-receptor.

14. The method or the therapeutic composition for use of any one of claims 12-13, wherein said co-receptor is an Fc receptor common y chain (FcRy).

15. The method or the therapeutic composition for use of any one of claims 9-14, wherein said Fc receptor is Fey receptor.

16. The method or the therapeutic composition for use of claim 15, wherein said Fey receptor is CD64.

17. The method or the therapeutic composition for use of any one of claims 1-16, wherein said immune cell is a T cell.

18. The method or the therapeutic composition for use of any one of claims 1-17, wherein said memory cell is an effector memory cell.

19. The method or the therapeutic composition for use of any one of claims 3-17, wherein said cancer is selected from the group consisting of melanoma, lymphoma, breast cancer, gastric cancer and ovarian cancer.

20. The method or the therapeutic composition for use of any one of claims 3-17, wherein said cancer is selected from the group consisting of lymphoma and gastric cancer.

21. The method or the therapeutic composition for use of any one of claims 1-20, being effected at least 2 months following said Fc-mediated immune cell therapy.

22. The method or the therapeutic composition for use of any one of claims 1-21, being effected following determining presence of said Fc-mediated immune cells in a lymphoid organ sample of said subject.

23. The method or the therapeutic composition for use of any one of claims 1-22, being at least a second line treatment.

Citation Information

Patent Citations

  • Endowing cells with antibody specificity

    EP0340793A2

  • Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

    US10577417B2

  • Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors

    US20080003225A1

  • Chimeric receptors and uses thereof in immune therapy

    US20150139943A1

  • Novel Synthetic Biology-Based ADCC Technology

    US20160355566A1